Open AccessEffectiveness of entecavir in preventing hepatocellular carcinoma development is genotype-dependent in hepatitis B virus-associated liver cirrhosis
Author(s) -
Kazuo Tarao,
Akira Nozaki,
Makoto Chuma,
Masataka Taguri,
Shin Maeda
Publication year - 2021
Publication title -
world journal of hepatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.913
H-Index - 55
ISSN - 1948-5182
DOI - 10.4254/wjh.v13.i1.144
Subject(s) - medicine , hepatocellular carcinoma , entecavir , cirrhosis , genotype , hepatitis b virus , virology , gastroenterology , virus , gene , lamivudine , genetics , biology
The oral nucleos(t)ide analogue, entecavir (ETV) was demonstrated to reduce the rate of hepatocellular carcinoma (HCC) in patients with hepatitis B virus (HBV)-associated liver cirrhosis. However, the reduction of HCC differs in various regions of the world.